![]() |
Name |
Fusaristatin B
|
Molecular Formula | C37H59N3O8 | |
IUPAC Name* |
4-[6,13-dimethyl-10-methylidene-2,5,9,12-tetraoxo-14-[(5E,7E)-3,7,11-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]butanoic acid
|
|
SMILES |
CCCCCCC(C)CC/C=C(\C)/C=C/C(=O)C(C)CCC1C(C(=O)NC(=C)C(=O)NCC(C(=O)NC(C(=O)O1)CCCC(=O)O)C)C
|
|
InChI |
InChI=1S/C37H59N3O8/c1-8-9-10-11-14-24(2)15-12-16-25(3)19-21-31(41)26(4)20-22-32-28(6)35(45)39-29(7)36(46)38-23-27(5)34(44)40-30(37(47)48-32)17-13-18-33(42)43/h16,19,21,24,26-28,30,32H,7-15,17-18,20,22-23H2,1-6H3,(H,38,46)(H,39,45)(H,40,44)(H,42,43)/b21-19+,25-16+
|
|
InChIKey |
GPCDCSLJICCCRP-KCBOQBCRSA-N
|
|
Synonyms |
Fusaristatin B; 4-[6,13-dimethyl-10-methylidene-2,5,9,12-tetraoxo-14-[(5E,7E)-3,7,11-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]butanoic acid
|
|
CAS | NA | |
PubChem CID | 16724413 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 673.9 | ALogp: | 7.4 |
HBD: | 4 | HBA: | 8 |
Rotatable Bonds: | 18 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 168.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 48 | QED Weighted: | 0.062 |
Caco-2 Permeability: | -5.098 | MDCK Permeability: | 0.00002420 |
Pgp-inhibitor: | 0.891 | Pgp-substrate: | 0.372 |
Human Intestinal Absorption (HIA): | 0.594 | 20% Bioavailability (F20%): | 0.951 |
30% Bioavailability (F30%): | 0.914 |
Blood-Brain-Barrier Penetration (BBB): | 0.051 | Plasma Protein Binding (PPB): | 98.97% |
Volume Distribution (VD): | 0.355 | Fu: | 1.68% |
CYP1A2-inhibitor: | 0.009 | CYP1A2-substrate: | 0.067 |
CYP2C19-inhibitor: | 0.052 | CYP2C19-substrate: | 0.098 |
CYP2C9-inhibitor: | 0.163 | CYP2C9-substrate: | 0.98 |
CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.272 |
CYP3A4-inhibitor: | 0.749 | CYP3A4-substrate: | 0.145 |
Clearance (CL): | 2.157 | Half-life (T1/2): | 0.881 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.77 |
Drug-inuced Liver Injury (DILI): | 0.183 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.618 | Maximum Recommended Daily Dose: | 0.96 |
Skin Sensitization: | 0.482 | Carcinogencity: | 0.223 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.025 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003015 | ![]() |
0.890 | D0I4DQ | ![]() |
0.268 | ||
ENC002373 | ![]() |
0.333 | D09SRR | ![]() |
0.265 | ||
ENC005276 | ![]() |
0.327 | D0H2YX | ![]() |
0.260 | ||
ENC005273 | ![]() |
0.314 | D0T9TJ | ![]() |
0.260 | ||
ENC005275 | ![]() |
0.313 | D0ZI4H | ![]() |
0.244 | ||
ENC005271 | ![]() |
0.311 | D0N3NO | ![]() |
0.244 | ||
ENC005272 | ![]() |
0.306 | D06FEA | ![]() |
0.244 | ||
ENC002514 | ![]() |
0.305 | D0V0IX | ![]() |
0.242 | ||
ENC003950 | ![]() |
0.305 | D03JSJ | ![]() |
0.242 | ||
ENC002057 | ![]() |
0.300 | D0K7NQ | ![]() |
0.239 |